Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - AYTU BIOPHARMA, INC | aytu_ex991.htm |
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): March 23, 2020
AYTU BIOSCIENCE, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-38247
|
|
47-0883144
|
|
(State
or other jurisdictionof incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
373 Inverness Parkway, Suite 206
Englewood, CO 80112
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code: (720) 437-6580
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common
Stock, par value $0.0001 per share
|
|
AYTU
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
On
March 23, 2020, Aytu BioScience, Inc. (the “Company"),
reported that it has received confirmation from the U.S. Food and
Drug Administration (FDA) that the company may begin distribution
of its Coronavirus Disease 2019 (“COVID-2019”) IgG/IgM
Rapid Test throughout the United States. The COVID-19 IgG/IgM Rapid
Test is intended for professional use and delivers results between
2 and 10 minutes at the point-of-care.
In
addition, the Company expects delivery of its first shipment of
100,000 tests this week. The Company has been in discussions with
healthcare distributors, healthcare institutions, medical
practices, and government agencies and is working quickly to begin
distribution into the U.S. healthcare supply chain.
Item
9.01 Financial Statements and Exhibits.
(d)
The following
exhibit is being filed herewith:
| Exhibit |
|
Description |
|
|
Press
Release dated March 23, 2020
|
1
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
AYTU BIOSCIENCE, INC.
|
|
|
|
|
|
|
Date:
March 23, 2020
|
By:
|
/s/
Joshua R. Disbrow
|
|
|
|
Joshua
R. Disbrow
|
|
|
|
Chief
Executive Officer
|
2